Alcon Inc. — FY2020 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 filing; the filing says fourth-quarter sales were in line with the prior year. Financial statements are prepared under IFRS and reported in U.S. dollars.
Business context
Alcon is a global eye-care company operating in Surgical and Vision Care. FY2020 net sales were $6.8 billion: Surgical products represented 55% and Vision Care 45%. The United States accounted for 44% of sales. The company cited COVID-19 disruption to elective procedures, customer demand, supply chains and operations.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Net sales to third parties | $6.763 billion | $7.362 billion |
| Gross profit / gross margin | $2.940 billion / 43.5% | $3.662 billion / 49.7% |
| Operating loss / operating margin | $482 million / (7.1%) | $187 million / (2.5%) |
| Net loss / loss per share | $531 million / $1.09 | $656 million / $1.34 |
| Core operating income / margin (non-IFRS) | $789 million / 11.7% | $1.265 billion / 17.2% |
| Core net income / diluted EPS (non-IFRS) | $512 million / $1.04 | $925 million / $1.89 |
| Net cash from operating activities | $823 million | $920 million |
| Free cash flow (non-IFRS) | $350 million | $367 million |
| Cash and cash equivalents | $1.557 billion | $822 million |
| Total financial debt / net debt | $4.118 billion / $2.558 billion | $3.479 billion / $2.656 billion |
FY2020 segment sales were $3.710 billion for Surgical, down 11% at constant currency, and $3.053 billion for Vision Care, down 4%. Surgical declines were broad, especially in consumables; Vision Care contact-lens sales fell 7%, while ocular health was approximately flat at constant currency.
Material changes and notable items
- Sales fell 8% at constant currency as COVID-19 restricted non-urgent procedures and reduced demand, particularly in Q2. Management reported a substantial recovery in the second half, with Q4 sales in line with the prior year.
- Operating loss widened despite a lower net loss. The operating result included $167 million of intangible-asset impairments, $217 million of separation costs and $49 million of transformation costs. It also benefited from a $154 million net gain on post-employment benefit plan amendments and other items.
- Core operating income declined 35% at constant currency, reflecting lower sales, $120 million of manufacturing under-absorption and labor inefficiencies, higher expected-credit-loss provisions and increased R&D investment. Discretionary spending reductions partly offset these impacts.
- Cash from operations decreased to $823 million. Free cash flow was $350 million after $479 million of property, plant and equipment purchases. Inventory rose $139 million, partly from launch-related builds and weaker pandemic demand.
- Alcon issued $750 million of 2.6% senior notes due 2030. Financial debt had an average maturity of 8.9 years; the $1 billion revolving credit facility was undrawn at year-end. The filing states there are no financial covenants and no major debt maturities before 2024.
- The reported tax benefit was $104 million, versus a $324 million tax expense in 2019, which included a substantial non-cash charge following Swiss tax reform.
Outlook, risks and contingencies
- Management expected COVID-19 to continue affecting results in the first half of 2021, with recovery varying by market; manufacturing capacity was expected to start normalizing in Q1. The filing provides no numerical FY2021 revenue or earnings guidance.
- Management described long-term opportunity from aging populations, greater access to eye care, premium procedures and daily disposable lenses, while pursuing product launches, innovation, market expansion and operating efficiencies. Its stated market-growth estimates are forecasts, not company guidance.
- The Board proposed a CHF 0.10-per-share dividend for shareholder approval in April 2021. Alcon had deferred its initial dividend proposal in 2020 because of pandemic-related uncertainty.
- Key risks include renewed procedure restrictions, pricing and reimbursement pressure, competition and product innovation risk, supply interruptions and reliance on some single-source suppliers, customer credit and collection risk, cyber/ERP implementation risk, currency volatility and the ability to service debt.
- Alcon is subject to a three-year U.S. Department of Justice deferred prosecution agreement entered in June 2020 concerning historical Vietnam distributor payments. The $8.925 million penalty was indemnified by Novartis; a breach could lead to prosecution or additional penalties.
- Pending disputes include contact-lens pricing class actions and patent/copyright litigation involving the LenSx system and UltraSert delivery system. Outcomes and potential losses are not clearly quantified in the filing.
- A Swiss tax-incentive claw-back obligation was CHF 520 million at year-end 2020, declining over time and due to expire at the end of 2022, subject to compliance with specified requirements.
- Alcon reported effective disclosure controls and internal control over financial reporting as of year-end; the independent auditor issued an unqualified opinion on the 2020 financial statements and controls.
Most important facts for investors to verify
- Whether sales and operating margins recover as elective procedures and customer activity normalize, and whether the reported Q4 trend continues.
- Drivers of the gap between IFRS operating results and core results, including recurring amortization, impairments, separation and transformation costs, and pension-plan gains.
- Cash conversion, inventory levels, receivable collections and the resulting net-debt trajectory.
- Progress and realized savings from the separation and transformation programs, alongside remaining costs and Novartis transition dependencies.
- Developments in the DOJ agreement, patent disputes, contact-lens litigation and CHF 520 million Swiss claw-back exposure.
- Shareholder approval and payment of the proposed CHF 0.10 dividend, and any subsequent numerical company guidance.